ABVC BioPharma Granted US Patent for ADHD Treatment Ingredient, Strengthening Pipeline
• ABVC BioPharma received a US patent for PDC-1421, an extract used in ABV-1505, its treatment for attention deficit/hyperactivity disorder (ADHD)
• The patent grants ABVC exclusive rights to sell PDC-1421 in the US until 2040 as it seeks global coverage
• ABV-1505 contains the patented PDC-1421 extract and has completed Phase IIa trials, with Phase IIb underway
• The global ADHD treatment market is valued at $16B currently and expected to reach $32B by 2030
• ABVC has an active pipeline of 6 drugs and 1 medical device, using licensed technology from Stanford, UC San Francisco, and Cedars-Sinai